Open | - |
Close | - |
Volume / Avg. | 25.000 / 257.881K |
Day Range | - - - |
52 Wk Range | 1.574 - 8.194 |
Market Cap | $262.406M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 47 |
Short Interest | 1.77% |
Days to Cover | 1.88 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Werewolf Therapeutics (NASDAQ: HOWL) through any online brokerage.
Other companies in Werewolf Therapeutics’s space includes: bluebird bio (NASDAQ:BLUE), Inovio Pharmaceuticals (NASDAQ:INO), Gritstone Bio (NASDAQ:GRTS), Mesoblast (NASDAQ:MESO) and Opthea (NASDAQ:OPT).
The latest price target for Werewolf Therapeutics (NASDAQ: HOWL) was reported by HC Wainwright & Co. on Thursday, March 7, 2024. The analyst firm set a price target for 15.00 expecting HOWL to rise to within 12 months (a possible 144.30% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Werewolf Therapeutics (NASDAQ: HOWL) is $6.14 last updated March 18, 2024 at 5:09 PM EDT.
There are no upcoming dividends for Werewolf Therapeutics.
Werewolf Therapeutics’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Werewolf Therapeutics.
Werewolf Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.